ClinicalTrials.gg
Active, not recruitingNCT05932862Updated Nov 6, 2026

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

A Phase 1 interventional study of XL309 and Olaparib in Advanced Solid Tumor, sponsored by Exelixis. Active, not recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

Updated Nov 6, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
429
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 276 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
134th of 1,499
429 · median 47
Started
2024
with 78 others
Phase 1
548 of 1,780
73 open now
Primary completion
2027-04
later than 177 of 450 live
Registered
1,542nd of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 134th largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 79 that started in 2024, is one of 548 in phase 1, reaches primary completion later than 177 of the 450 other live ones, and was the 1,542nd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

276 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

271 more — sign in →

All 276 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.

03

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Ovarian Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Advanced HRRm Solid Tumors
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Capable of understanding and complying with protocol requirements.
  2. Male or female aged 18 years or older.
  3. performance status 0 or 1.
  4. Adequate bone marrow and organ function.
  5. Participant-disease Characteristics

    Dose-Escalation Stage Single Agent and Combination:

    a) Participants whose tumor progressed on, or who were intolerant to standard therapy, have a disease for which no therapy exists or are not a candidate for these therapies, and have one of the following cancers:

    i. confirmed locally advanced/ human epidermal growth factor receptor-2 ()-negative breast cancer, with deleterious or suspected deleterious breast cancer gene (BRCA)1/2 alteration.

    ii. Histologically confirmed locally advanced/metastatic high-grade serous ovarian cancer (HGSOC), including primary peritoneal cancer (PPC) and fallopian tube cancer (FTC).

    iii. Histologically confirmed locally advanced/metastatic CRPC, with deleterious or suspected deleterious BRCA1/2 alteration.

    iv. Histologically confirmed locally advanced/metastatic pancreatic cancer with deleterious or suspected deleterious BRCA1/2 alteration.

    v. Locally advanced/metastatic tumors with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) mutation or homologous recombination deficiency (HRD) phenotype.

    Cohort-Expansion Stage Single Agent and Combination:

    b) HER2-negative breast cancer cohort: participants with histologically confirmed locally advanced/metastatic (HER2)-negative breast cancer with alterations in select HRR genes.

    c) Platinum-sensitive HGSOC cohort: participants with histologically confirmed locally advanced/metastatic HGSOC, including primary peritoneal cancer (PPC) and fallopian tube cancer (FTC), with positive HRD result using an approved diagnostic, and/or alterations in select HRR genes.

    d) mCRPC cohort: participants with metastatic, castration-resistant adenocarcinoma of the prostate with alterations in select HRR genes.

    e) HRRm advanced solid tumors cohort: participants with locally advanced/metastatic tumors with alterations in select HRR genes.

    For all participants with solid tumors:

  6. Participants in the Cohort-Expansion Stage must have at least 1 measurable target lesion.
  7. Recovery to baseline or ≤ Grade 1 v5 from AE(s) related to any prior treatments.

Key Exclusion Criteria

  1. Prior anticancer treatment including:

    1. Small molecule-targeted therapy \< 5 half-lives from first dose of study treatment, or 3 weeks (whichever is shorter).
    2. Any antibody therapy \< 5 half-lives from first dose of study treatment (or 4 weeks since last therapy, whichever is shorter).
    3. Chemotherapy with nitrosoureas or mitomycin C \< 6 weeks from first dose of study treatment. Other chemotherapy \< 3 weeks prior to first dose of study treatment.
    4. Radiation therapy (including radiofrequency ablation) \< 1 week prior to initiation of study treatment. Participants with ongoing complications from prior radiation therapy are not eligible.
  2. Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
  3. History of to any of XL309, or history of allergic reactions attributed to drugs with a similar chemical or biologic structure or class to XL309.
  4. Lactating or pregnant females.
  5. Clinically relevant cardiovascular disease.
  6. Known history of myelodysplastic syndrome.
  7. Other severe, acute, or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of the study results, and in the judgment of the investigator, would make the participant inappropriate for the study.
  8. Inability or unwillingness to comply with requirement for oral drug administration or presence of a gastrointestinal condition that would preclude adequate absorption of XL309.
  9. Prior treatment with a ubiquitin specific peptidase 1 (USP1) inhibitor.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
429 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Single Agent Evaluation

    Participants will receive XL309 in sequential cohorts of increasing doses.

    Drug: XL309

  • Experimental
    Dose Escalation Combination Therapy

    Participants will receive XL309 in sequential cohorts of increasing doses in combination with olaparib.

    Drug: XL309 · Drug: Olaparib

  • Experimental
    Cohort Expansion Stage Single Agent Evaluation

    The recommended dose as determined in the Escalation Stage will be further studied in advanced solid tumor-specific cohorts.

    Drug: XL309

  • Experimental
    Cohort Expansion Stage Combination Therapy Evaluation

    The recommended dose as determined in the Escalation Stage will be further studied in combination with olaparib in advanced solid tumor-specific cohorts.

    Drug: XL309 · Drug: Olaparib

Interventions

  • DrugXL309

    XL309 will be administered orally per assigned schedule.

    Also known as: ISM3091

  • Olaparib will be administered orally per assigned schedule.

06

What researchers measure

Primary outcomes

  1. Dose Escalation Stage: Incidence of TEAEs and SAEs; AEs Leading to Dose Modification, Discontinuation, or Death; and Laboratory Abnormalities

    Adverse events will be recorded and severity graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Approximately 24 months

  2. Dose Escalation Stage: Incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: Approximately 24 months

  3. Dose Escalation Stage: XL309 Exposure Over Time Measured as Area Under the Plasma Concentration Curve (AUC)

    Time frame: Approximately 24 months

  4. Dose Escalation Stage: XL309 Maximum Plasma Concentration (Cmax)

    Time frame: Approximately 24 months

  5. Dose Escalation Stage: XL309 Time to Cmax

    Time frame: Approximately 24 months

  6. Dose Escalation Stage: XL309 Trough Concentration (Ctrough)

    Lowest concentration of drug in the bloodstream, measured just before the next dose is administered.

    Time frame: Approximately 24 months

  7. Dose Escalation Stage: XL309 Apparent Clearance (CL/F)

    Time frame: Approximately 24 months

  8. Cohort Expansion Stage: Incidence of TEAEs and SAEs; AEs Leading to Dose Modification, Discontinuation, or Death; and Laboratory Abnormalities

    Adverse events will be recorded and severity graded using CTCAE version 5.0.

    Time frame: Approximately 24 months

  9. Cohort Expansion Stage: Objective Response Rate (ORR)

    ORR will be measured per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the Investigator. ORR for prostate cancer will be based on Prostate Cancer Working Group 3 (PCWG3) criteria, as assessed by the Investigator

    Time frame: Approximately 24 months

Secondary outcomes

  1. Dose Escalation Stage: Olaparib Exposure Over Time Measured as Area Under the Plasma Concentration Curve (AUC) at Steady State

    Time frame: Approximately 24 months

  2. Dose Escalation Stage: Olaparib Cmax at Steady State

    Time frame: Approximately 24 months

  3. Dose Escalation Stage: Olaparib Ctrough at Steady State

    Time frame: Approximately 24 months

  4. Cohort Expansion Stage: Concentration of XL309 in Plasma at Specified Time Points

    Time frame: Approximately 24 months

  5. Cohort Expansion Stage: Concentration of Olaparib in Plasma at Specified Time Points

    Time frame: Approximately 24 months

07

Study locations

13 sites
  • Exelixis Clinical Site #15
    Jacksonville, Florida 32224, United States
  • Exelixis Clinical Site #8
    Orlando, Florida 32827, United States
  • Exelixis Clinical Site #16
    Tampa, Florida 33612, United States
  • Exelixis Clinical Site #14
    Rochester, Minnesota 55905, United States
  • Exelixis Clinical Site #9
    New Brunswick, New Jersey 08901, United States
  • Exelixis Clinical Site #5
    New York, New York 10029, United States
  • Exelixis Clinical Site #7
    Cleveland, Ohio 44106, United States
  • Exelixis Clinical Site #13
    Oklahoma City, Oklahoma 73104, United States
  • Exelixis Clinical Site #11
    Germantown, Tennessee 38138, United States
  • Exelixis Clinical Site #6
    Nashville, Tennessee 37203, United States
  • Exelixis Clinical Site #4
    Austin, Texas 78758, United States
  • Exelixis Clinical Site #1
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #3
    San Antonio, Texas 78229, United States
08

References and documents

Publications

  • Mi X, Li Q, Long G, Pan Y, Xie Y, Lu S, Xiao L, Tang J, Zhou L. Deubiquitylating Enzymes in Hepatocellular Carcinoma. Int J Biol Sci. 2025 Jun 20;21(9):4270-4292. doi: 10.7150/ijbs.113193. eCollection 2025. PubMed 40607251 ↗
  • da Costa AA, Somuncu O, Ravindranathan R, Mukkavalli S, Martignetti DB, Nguyen H, Jiao Y, Lamarre BP, Sadatrezaei G, Moreau L, Liu J, Iyer DR, Lazaro JB, Shapiro GI, Parmar K, D'Andrea AD. Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity. Cancer Res. 2024 Oct 15;84(20):3435-3446. doi: 10.1158/0008-5472.CAN-23-4007. PubMed 38885312 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 36 months is below that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jan 2029 → Apr 2027 and completion Aug 2029 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 6, 2023
StartActual
Apr 3, 2024
Primary completionEst.
Apr 30, 2027was Jan 2029
CompletionEst.
Dec 31, 2027was Aug 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Sites
3 sites removed
Show 3 removed
  • Exelixis Clinical Site #12 · Fountain Valley, United States
  • Exelixis Clinical Site #10 · Kansas City, United States
  • Exelixis Clinical Site #2 · Houston, United States
Nov 6, 2026
Primary completion
Jan 3, 2029→Apr 30, 2027
Nov 6, 2026
Study completion
Aug 3, 2029→Dec 31, 2027
Nov 6, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40607251 ↗
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40607251 ↗
    3 sites removed
    Show 3 removed
    • Exelixis Clinical Site #12 · Fountain Valley, United States
    • Exelixis Clinical Site #10 · Kansas City, United States
    • Exelixis Clinical Site #2 · Houston, United States
    Primary completion Jan 3, 2029→Apr 30, 2027
    Study completion Aug 3, 2029→Dec 31, 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05932862
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Apr 3, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion